3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
200 recruiting
3
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Corbus Pharmaceuticals, Inc. is a company with 3 orphan drug designations across 3 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cystic fibrosis | (6aR, 10aR)-3-(1¿,1¿-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid | Des.TrialAppr. |
| dermatomyositis | lenabasum | Des.TrialAppr. |
| systemic sclerosis | (6aR, 10aR)-3-(1⿿,1⿿-dimethylheptyl)-ο8-tetrahydro-cannabinol-9-carboxylic acid | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
1
affecting portfolio